GenSight Biologics
Develops innovative therapies for mitochondrial and neurodegenerative diseases.
Launch date
Employees
Market cap
€39.8m
Enterprise valuation
€56m (Public information from Sep 2024)
Share price
€0.376 SIGHT.PA
Company register number 751164757
Paris Île-de-France (HQ)
Financials
Estimates*
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 4.4m | 5.3m | 2.6m | 1.3m | 5.5m | 7.3m | 5.7m |
| % growth | 528 % | 20 % | (51 %) | (51 %) | 330 % | 33 % | (21 %) |
| EBITDA | (24.0m) | (26.8m) | (26.4m) | (27.7m) | (23.9m) | (21.0m) | (28.7m) |
| % EBITDA margin | (546 %) | (509 %) | (1024 %) | (2189 %) | (439 %) | (290 %) | (504 %) |
| Profit | (34.0m) | (28.6m) | (27.6m) | (26.2m) | (24.7m) | (36.4m) | (66.2m) |
| % profit margin | (774 %) | (542 %) | (1070 %) | (2069 %) | (453 %) | (502 %) | (1161 %) |
| EV / revenue | 65.0x | 43.8x | 62.9x | 37.1x | 15.8x | 16.6x | 32.3x |
| EV / EBITDA | -11.9x | -8.6x | -6.1x | -1.7x | -3.6x | -5.7x | -6.4x |
| R&D budget | 22.0m | 22.6m | 18.9m | 19.4m | - | - | - |
| R&D % of revenue | 500 % | 427 % | 733 % | 1528 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
* | N/A | €22.5m | Post IPO Equity |
$9.1m | Post IPO Equity | ||
$16.6m | Post IPO Debt | ||
€25.0m Valuation: €167m 238.1x EV/LTM Revenues -5.7x EV/LTM EBITDA | Private Placement VC | ||
| N/A | €30.0m | Post IPO Equity | |
* | €12.0m | Post IPO Convertible | |
* | €6.0m | Post IPO Convertible | |
* | N/A | €4.0m | Post IPO Convertible |
* | N/A | €9.3m | Private Placement VC |
* | N/A | €9.3m | Post IPO Equity |
| Total Funding | €99.0m | ||
Related Content
Recent News about GenSight Biologics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.